Partnership opportunities

Our Business Development team are recognised for their experience in intellectual property management and commercialisation. The team, along with our researchers, have developed a strong pipeline of translatable biomedical discoveries. Our focus is on the translation of our research to deliver health benefits to the community, increasingly this requires commercial partnerships to progress our discoveries through to the marketplace. Below are some of our research and technology expertise areas, contact us if you are interested in these or if you have specific area you would like to pursue.


Central Nervous System
SRY inhibition to treat Parkinson’s Disease in males
Treatment for White Matter Impairment in Newborns

Gene Therapy
RNA interference with Potent Immune System Activation
SRY inhibition to treat Parkinson’s Disease in males

Infectious Diseases
TLR7/8 Antagonists: Anti-bacterial and Anti-inflammatory Agents

Inflammation
Exosome Therapy – a cell-free approach to regenerative medicine
RNA interference with Potent Immune System Activation
TLR7/8 Antagonists: Anti-bacterial and Anti-inflammatory Agents

Oncology
Small molecule inhibitors of liver Receptor Homolgo-1 (LRH-1)

Paediatrics
– 
Treatment for White Matter Impairment in Newborns

Reproductive Health
Treating pelvic organ prolapse. A tissue engineering approach using novel designed scaffolds embedded with autologous endometrial mesenchymal stem cells.

Regenerative Medicine
Exosome Therapy – a cell-free approach to regenerative medicine

Women’s Health
Treating pelvic organ prolapse. A tissue engineering approach using novel designed scaffolds embedded with autologous endometrial mesenchymal stem cells.


Contact Us

Mr Rob Merriel
Business Development Director
tel +61 3 8572 2553
rob.merriel@hudson.org.au


Dr Nadine Brew
Business Development Coordinator
tel +61 3 8572 2528
nadine.brew@hudson.org.au